AAA
MDGL icon

Affinity Asset Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Affinity Asset Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,000
Closed -$4.87M – 73
2022
Q3 		$4.87M Buy
+75,000
New +$5.21M 1.36% 21

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Affinity Asset Advisors's MDGL Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 27% in Q2 2026, selling an estimated $7.68M and leaving 40,000 shares worth $21.5M. The position accounts for 0.97% of the portfolio, ranked #32.

Affinity Asset Advisors first reported a position in MDGL in Q4 2020 and has held it in 20 quarters since. The position peaked at $52.7M in Q3 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Affinity Asset Advisors held 40,000 shares of Madrigal Pharmaceuticals worth $21.5M as of Q2 2026.
  • Affinity Asset Advisors sold 15,000 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.68M.
  • Madrigal Pharmaceuticals made up 0.97% of Affinity Asset Advisors's portfolio in Q2 2026, its #32 holding.
  • Affinity Asset Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Affinity Asset Advisors's Madrigal Pharmaceuticals position peaked at $52.7M in Q3 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.